Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGenedrive Regulatory News (GDR)

Share Price Information for Genedrive (GDR)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1.625
Bid: 1.60
Ask: 1.65
Change: 0.00 (0.00%)
Spread: 0.05 (3.125%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 1.625
GDR Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Holding(s) in Company

30 Apr 2010 09:42

RNS Number : 1189L
Epistem Holdings plc
30 April 2010
 

 

TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARESi

1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached: ii

Epistem Holdings plc

 

 

 

 

 

2 Reason for the notification (please tick the appropriate box or boxes):

An acquisition or disposal of voting rights

X

An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached

An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments

An event changing the breakdown of voting rights

Other (please specify):

3. Full name of person(s) subject to the notification obligation: iii

Octopus Investments Nominees Limited

4. Full name of shareholder(s)  (if different from 3.):iv

5. Date of the transaction and date on which the threshold is crossed or reached: v

16/04/10

6. Date on which issuer notified:

29/04/10

7. Threshold(s) that is/are crossed or reached: vi, vii

4%

 

8. Notified details:

A: Voting rights attached to shares viii, ix

Class/type of shares

if possible using the ISIN CODE

Situation previous to the triggering transaction

Resulting situation after the triggering transaction

Number of Shares

Number of Voting Rights

Number of shares

Number of voting rights

% of voting rights x

Direct

Direct xi

Indirect xii

Direct

Indirect

GB00B1VKB244

 

364300

 

364300

 

315000

 

315000

 

3.97%

B: Qualifying Financial Instruments

Resulting situation after the triggering transaction

Type of financial instrument

Expiration date xiii

Exercise/ Conversion Period xiv

Number of voting rights that may be acquired if the instrument is exercised/ converted.

% of voting rights

C: Financial Instruments with similar economic effect to Qualifying Financial Instruments xv, xvi

Resulting situation after the triggering transaction

Type of financial instrument

Exercise price

Expiration date xvii

Exercise/ Conversion period xviii

Number of voting rights instrument refers to

 

% of voting rights xix, xx

 

 

 

Nominal

Delta

Total (A+B+C)

Number of voting rights

Percentage of voting rights

315000

 

3.97%

 

9. Chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held, if applicable: xxi

 

N/A

Proxy Voting:

10. Name of the proxy holder:

N/A

11. Number of voting rights proxy holder will cease to hold:

N/A

12. Date on which proxy holder will cease to hold voting rights:

N/A

13. Additional information:

14. Contact name:

Russell Jarvis

15. Contact telephone number:

020 7710 8653

 

Note: Annex should only be submitted to the FSA not the issuer

Annex: Notification of major interests in share

A: Identity of the persons or legal entity subject to the notification obligation

Full name

(including legal form of legal entities)

 

Peter Orsi

Contact address

(registered office for legal entities)

 

8 Angel Court, London, EC2R 7HP

Phone number & email

 

020 7710 8653

Other useful information

(at least legal representative for legal persons)

 

B: Identity of the notifier, if applicable

Full name

 

Contact address

 

Phone number & email

 

Other useful information

(e.g. functional relationship with the person or legal entity subject to the notification obligation)

C: Additional information

For notes on how to complete form TR-1 please see the FSA website.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
HOLUROWRRWASORR
Date   Source Headline
31st May 20237:00 amRNSBlock Listing Returns
19th May 20237:00 amRNSNICE recommends CYP2C19 genotyping
15th May 20235:56 pmRNSBlock Listing Application to AIM
11th May 202311:58 amRNSResult of General Meeting
24th Apr 202311:54 amRNSPublication of Circular and Notice of GM
11th Apr 20235:44 pmRNSHolding(s) in Company
6th Apr 20238:00 amRNSTotal Voting Rights
31st Mar 20236:32 pmRNS£5 million Equity Prepayment Facility
31st Mar 20236:32 pmRNSHalf-year Report
30th Mar 20234:35 pmRNSPrice Monitoring Extension
30th Mar 20239:05 amRNSSecond Price Monitoring Extn
30th Mar 20239:00 amRNSPrice Monitoring Extension
30th Mar 20237:00 amRNSPositive final recommendation by NICE
23rd Mar 20234:35 pmRNSPrice Monitoring Extension
20th Mar 20237:00 amRNSCommence of roll out in Greater Manchester
9th Feb 20232:05 pmRNSSecond Price Monitoring Extn
9th Feb 20232:00 pmRNSPrice Monitoring Extension
9th Feb 20239:05 amRNSSecond Price Monitoring Extn
9th Feb 20239:00 amRNSPrice Monitoring Extension
9th Feb 20237:00 amRNSAIHL test preliminary recommendation by NICE
27th Jan 20232:05 pmRNSSecond Price Monitoring Extn
27th Jan 20232:00 pmRNSPrice Monitoring Extension
26th Jan 20234:40 pmRNSSecond Price Monitoring Extn
26th Jan 20234:35 pmRNSPrice Monitoring Extension
26th Jan 20232:05 pmRNSSecond Price Monitoring Extn
26th Jan 20232:00 pmRNSPrice Monitoring Extension
25th Jan 20234:40 pmRNSSecond Price Monitoring Extn
25th Jan 20234:35 pmRNSPrice Monitoring Extension
19th Jan 20234:40 pmRNSSecond Price Monitoring Extn
19th Jan 20234:35 pmRNSPrice Monitoring Extension
29th Dec 20226:10 pmRNSResult of AGM
5th Dec 20227:00 amRNSNotice of AGM
30th Nov 20227:00 amRNSBlock Listing Six Monthly Return
21st Nov 20227:00 amRNSAudited Final Results
14th Nov 20227:00 amRNSNotice of Results
24th Oct 20227:00 amRNSGrant of options
5th Oct 20224:40 pmRNSSecond Price Monitoring Extn
5th Oct 20224:35 pmRNSPrice Monitoring Extension
5th Oct 20227:00 amRNSUS FDA pre-submission for Genedrive MT-RNR1 kit
26th Sep 20227:00 amRNSNICE to accelerate evaluation of Genedrive test
22nd Aug 20227:00 amRNSNICE includes CYP2C19-ID Kit in new programme
5th Jul 20222:06 pmRNSSecond Price Monitoring Extn
5th Jul 20222:00 pmRNSPrice Monitoring Extension
16th Jun 20227:00 amRNSNICE to evaluate the Genedrive® MT-RNR1 Test
30th May 20229:05 amRNSSecond Price Monitoring Extn
30th May 20229:00 amRNSPrice Monitoring Extension
30th May 20227:00 amRNSPoint-of-Care COV19-ID Kit receives CTDA approval
27th May 20227:00 amRNSBlock listing Interim Review
25th Apr 20229:05 amRNSSecond Price Monitoring Extn
25th Apr 20229:00 amRNSPrice Monitoring Extension

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.